Product Description
Mechanisms of Action: EGFR Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Indonesia | Philippines | Thailand | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Seoul National University Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Stomatitis|Mucositis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EGFOM | P2 |
Completed |
Stomatitis|Mucositis |
2014-10-01 |